• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 7, 2017

View Archived Issues

Pew joins AMR fight, aims to SPARK discovery research

LONDON – The Pew Charitable Trusts is stepping in to fill a gap in the international fight against antimicrobial resistance (AMR), with the formation of a virtual laboratory that will bring together disparate datasets and leading experts in an open platform for use by industry, academics and nonprofits. Read More

Bench Press: BioWorld looks at translational medicine

Activating mutations in the BRAF kinase, such as those targeted by melanoma drug Zelboraf (vemurafenib, Roche Holding AG), are a well-known cause of cancer. Read More

Other news to note

Omeros Corp., of Seattle, said the FDA granted orphan designation to OMS-721, its lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2, in immunoglobulin A (IgA) nephropathy. Read More

In the clinic

Infinity Pharmaceuticals Inc., of Cambridge, Mass., said it completed the monotherapy dose-escalation portion of its four-part phase I trial testing IPI-549 in patients with advanced solid tumors. Read More

Earnings

Spectrum Pharmaceuticals Inc., of Henderson, Nev., reported total revenue of $34 million in the second quarter. Read More

Financings

Neovacs SA, of Paris, said it closed its €6 million (US$7.1 million) share capital increase via private placement. Proceeds will support the company's development plan for IFNalpha Kinoid, including completion of a phase IIb trial in lupus, a phase IIa trial in dermatomyositis and preclinical proof-of-concept testing in type 1 diabetes. Read More

Australia considers naming requirements for biosimilars, input from overseas regulators

PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is asking for industry feedback on whether Australia should change its naming mechanisms for biosimilars and biologics and if it should adopt practices of other international regulators. Read More

Mallinckrodt to acquire Infacare for its severe jaundice drug

Mallinckrodt plc said it plans to acquire Infacare Pharmaceutical Corp., the developer of a late-stage severe jaundice treatment, for $80 million up front plus up to $345 million in potential milestone payments. If approved, the FDA fast-tracked candidate, stannsoporfin, could potentially be used to reduce or prevent the need for phototherapy, risky exchange transfusions and the incidence of pricey hospital readmissions. Read More

BMS looks to 'marry' adaptive, innate immunity with $2.32B+ IFM buy

Two-year-old IFM Therapeutics Inc. became the latest biopharma unicorn, as Bristol-Myers Squibb Co. (BMS) picked up the Boston-based company for $300 million up front and another $1.01 billion in potential development, regulatory and sales milestones for each of the first products from the deal's two oncology programs. IFM is eligible for more contingent milestone payments for additional products that emerge from the programs. Read More

Maverick Mavyret's label distinguishes HCV winner for Abbvie; whither Gilead?

Enanta Pharmaceuticals Inc. CEO Jay Luly told BioWorld that, with the FDA's approval for Abbvie Inc.'s hepatitis C virus (HCV) drug Mavyret (glecaprevir/pibrentasvir), his firm is one milestone away from hitting every goal set by the deal. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe